tiprankstipranks
Trending News
More News >
Altimmune (ALT)
:ALT
US Market

Altimmune (ALT) Stock Forecast & Price Target

Compare
3,391 Followers
See the Price Targets and Ratings of:

ALT Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
8 Buy
2 Hold
1 Sell
Based on 11 analysts giving stock ratings to
Altimmune
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALT Stock 12 Month Forecast

Average Price Target

$17.75
▲(303.41%Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $17.75 with a high forecast of $28.00 and a low forecast of $1.00. The average price target represents a 303.41% change from the last price of $4.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","29":"$29","7.25":"$7.25","14.5":"$14.5","21.75":"$21.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,7.25,14.5,21.75,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.23,6.058461538461539,7.886923076923077,9.715384615384615,11.543846153846154,13.372307692307693,15.20076923076923,17.029230769230768,18.857692307692307,20.686153846153847,22.514615384615386,24.34307692307692,26.17153846153846,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.23,5.2700000000000005,6.3100000000000005,7.3500000000000005,8.39,9.43,10.47,11.510000000000002,12.55,13.59,14.63,15.670000000000002,16.71,{"y":17.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.23,3.981538461538462,3.7330769230769234,3.484615384615385,3.2361538461538464,2.987692307692308,2.73923076923077,2.490769230769231,2.2423076923076923,1.993846153846154,1.7453846153846158,1.496923076923077,1.2484615384615387,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.00Average Price Target$17.75Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ALT
TipRanks AITipRanks
Not Ranked
TipRanks
$5
Hold
13.64%
Upside
Reiterated
07/03/25
Altimmune's overall stock score reflects significant challenges in financial performance and valuation, offset by positive earnings call guidance and a strong balance sheet. Technical indicators suggest a bearish trend, but potential growth in new therapeutic areas and financial flexibility provide some optimism.
Citizens JMP Analyst forecast on ALT
Jonathan WollebenCitizens JMP
Citizens JMP
$25$15
Buy
240.91%
Upside
Reiterated
07/10/25
Altimmune price target lowered to $15 from $25 at Citizens JMPAltimmune price target lowered to $15 from $25 at Citizens JMP
Goldman Sachs Analyst forecast on ALT
Corinne JohnsonGoldman Sachs
Goldman Sachs
$1
Sell
-77.27%
Downside
Initiated
07/10/25
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development
Evercore ISI Analyst forecast on ALT
Liisa BaykoEvercore ISI
Evercore ISI
$25
Buy
468.18%
Upside
Reiterated
06/27/25
Analysts Are Bullish on These Healthcare Stocks: Chemed (CHE), Altimmune (ALT)
Piper Sandler Analyst forecast on ALT
Yasmeen RahimiPiper Sandler
Piper Sandler
$25
Buy
468.18%
Upside
Reiterated
06/27/25
Optimistic Outlook for Altimmune's Pemvidutide Despite Phase 2b Setback
UBS
$26
Buy
490.91%
Upside
Reiterated
06/27/25
UBS reiterates Buy Rating on Altimmune (ALT)UBS analyst Eliana Merle reiterated a Buy rating and $26.00 price target on Altimmune (NASDAQ: ALT).
William Blair Analyst forecast on ALT
Andy HsiehWilliam Blair
William Blair
Hold
Reiterated
06/26/25
William Blair Sticks to Its Hold Rating for Altimmune (ALT)
Stifel Nicolaus Analyst forecast on ALT
Annabel SamimyStifel Nicolaus
Stifel Nicolaus
$18
Buy
309.09%
Upside
Initiated
06/26/25
Altimmune's Pemvi hits MASH goal, shows broad potential, says StifelAltimmune's Pemvi hits MASH goal, shows broad potential, says Stifel
H.C. Wainwright Analyst forecast on ALT
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$12
Buy
172.73%
Upside
Reiterated
06/26/25
Altimmune's Pemvidutide: Promising Phase 2b Results Reinforce Buy Rating Amid Stock Decline
B.Riley Financial Analyst forecast on ALT
Mayank MamtaniB.Riley Financial
B.Riley Financial
$20
Buy
354.55%
Upside
Reiterated
06/26/25
Altimmune price target under review after pemvi data, says B. RileyAltimmune price target under review after pemvi data, says B. Riley
Jefferies Analyst forecast on ALT
Roger SongJefferies
Jefferies
$28
Buy
536.36%
Upside
Reiterated
06/26/25
Altimmune's Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential
AI Firm
$7$7.5
Hold
70.45%
Upside
Reiterated
06/13/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ALT
TipRanks AITipRanks
Not Ranked
TipRanks
$5
Hold
13.64%
Upside
Reiterated
07/03/25
Altimmune's overall stock score reflects significant challenges in financial performance and valuation, offset by positive earnings call guidance and a strong balance sheet. Technical indicators suggest a bearish trend, but potential growth in new therapeutic areas and financial flexibility provide some optimism.
Citizens JMP Analyst forecast on ALT
Jonathan WollebenCitizens JMP
Citizens JMP
$25$15
Buy
240.91%
Upside
Reiterated
07/10/25
Altimmune price target lowered to $15 from $25 at Citizens JMPAltimmune price target lowered to $15 from $25 at Citizens JMP
Goldman Sachs Analyst forecast on ALT
Corinne JohnsonGoldman Sachs
Goldman Sachs
$1
Sell
-77.27%
Downside
Initiated
07/10/25
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development
Evercore ISI Analyst forecast on ALT
Liisa BaykoEvercore ISI
Evercore ISI
$25
Buy
468.18%
Upside
Reiterated
06/27/25
Analysts Are Bullish on These Healthcare Stocks: Chemed (CHE), Altimmune (ALT)
Piper Sandler Analyst forecast on ALT
Yasmeen RahimiPiper Sandler
Piper Sandler
$25
Buy
468.18%
Upside
Reiterated
06/27/25
Optimistic Outlook for Altimmune's Pemvidutide Despite Phase 2b Setback
UBS
$26
Buy
490.91%
Upside
Reiterated
06/27/25
UBS reiterates Buy Rating on Altimmune (ALT)UBS analyst Eliana Merle reiterated a Buy rating and $26.00 price target on Altimmune (NASDAQ: ALT).
William Blair Analyst forecast on ALT
Andy HsiehWilliam Blair
William Blair
Hold
Reiterated
06/26/25
William Blair Sticks to Its Hold Rating for Altimmune (ALT)
Stifel Nicolaus Analyst forecast on ALT
Annabel SamimyStifel Nicolaus
Stifel Nicolaus
$18
Buy
309.09%
Upside
Initiated
06/26/25
Altimmune's Pemvi hits MASH goal, shows broad potential, says StifelAltimmune's Pemvi hits MASH goal, shows broad potential, says Stifel
H.C. Wainwright Analyst forecast on ALT
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$12
Buy
172.73%
Upside
Reiterated
06/26/25
Altimmune's Pemvidutide: Promising Phase 2b Results Reinforce Buy Rating Amid Stock Decline
B.Riley Financial Analyst forecast on ALT
Mayank MamtaniB.Riley Financial
B.Riley Financial
$20
Buy
354.55%
Upside
Reiterated
06/26/25
Altimmune price target under review after pemvi data, says B. RileyAltimmune price target under review after pemvi data, says B. Riley
Jefferies Analyst forecast on ALT
Roger SongJefferies
Jefferies
$28
Buy
536.36%
Upside
Reiterated
06/26/25
Altimmune's Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential
AI Firm
$7$7.5
Hold
70.45%
Upside
Reiterated
06/13/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Altimmune

1 Month
xxx
Success Rate
10/17 ratings generated profit
59%
Average Return
+15.51%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.82% of your transactions generating a profit, with an average return of +15.51% per trade.
3 Months
xxx
Success Rate
9/17 ratings generated profit
53%
Average Return
+34.22%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +34.22% per trade.
1 Year
Mayank MamtaniB.Riley Financial
Success Rate
15/37 ratings generated profit
41%
Average Return
+4.66%
reiterated a buy rating 15 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 40.54% of your transactions generating a profit, with an average return of +4.66% per trade.
2 Years
xxx
Success Rate
15/40 ratings generated profit
38%
Average Return
-11.07%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -11.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALT Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
18
17
18
18
15
Buy
0
0
0
0
0
Hold
3
4
6
7
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
1
total
21
21
24
25
22
In the current month, ALT has received 15 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. ALT average Analyst price target in the past 3 months is 17.75.
Each month's total comprises the sum of three months' worth of ratings.

ALT Financial Forecast

ALT Earnings Forecast

Next quarter’s earnings estimate for ALT is -$0.33 with a range of -$0.42 to -$0.26. The previous quarter’s EPS was -$0.26. ALT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.65% of the time in the same period. In the last calendar year ALT has Outperformed its overall industry.
Next quarter’s earnings estimate for ALT is -$0.33 with a range of -$0.42 to -$0.26. The previous quarter’s EPS was -$0.26. ALT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.65% of the time in the same period. In the last calendar year ALT has Outperformed its overall industry.

ALT Sales Forecast

Next quarter’s sales forecast for ALT is $1.00K with a range of $0.00 to $5.00K. The previous quarter’s sales results were $5.00K. ALT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 51.30% of the time in the same period. In the last calendar year ALT has Outperformed its overall industry.
Next quarter’s sales forecast for ALT is $1.00K with a range of $0.00 to $5.00K. The previous quarter’s sales results were $5.00K. ALT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 51.30% of the time in the same period. In the last calendar year ALT has Outperformed its overall industry.

ALT Stock Forecast FAQ

What is ALT’s average 12-month price target, according to analysts?
Based on analyst ratings, Altimmune’s 12-month average price target is 17.75.
    What is ALT’s upside potential, based on the analysts’ average price target?
    Altimmune has 303.41% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALT a Buy, Sell or Hold?
          Altimmune has a consensus rating of Moderate Buy which is based on 8 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Altimmune’s price target?
            The average price target for Altimmune is 17.75. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $28.00 ,the lowest forecast is $1.00. The average price target represents 303.41% Increase from the current price of $4.4.
              What do analysts say about Altimmune?
              Altimmune’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of ALT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis